AR087069A1 - Procesos e intermediarios para producir azaindoles - Google Patents
Procesos e intermediarios para producir azaindolesInfo
- Publication number
- AR087069A1 AR087069A1 ARP120102438A ARP120102438A AR087069A1 AR 087069 A1 AR087069 A1 AR 087069A1 AR P120102438 A ARP120102438 A AR P120102438A AR P120102438 A ARP120102438 A AR P120102438A AR 087069 A1 AR087069 A1 AR 087069A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- occurrences
- optionally substituted
- unsubstituted
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 6
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- -1 -NHCH3 Chemical group 0.000 abstract 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000008601 Polycythemia Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 206010028537 myelofibrosis Diseases 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052723 transition metal Inorganic materials 0.000 abstract 1
- 150000003624 transition metals Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Steroid Compounds (AREA)
Abstract
La presente se refiere a procesos e intermediarios para la preparación de los compuestos útiles como inhibidores de las quinasas Janus (JAK). Estos compuestos son útiles en el tratamiento de dolencias tales como las enfermedades autoinmunes (alergia, asma), rechazo de transplantes, leucemia, linfomas, policitemia, trombocitemia esencial, mielofibrosis. Reivindicación 1: Un proceso para preparar un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, caracterizada porque: R¹ es -H, -Cl o -F; R² es -H o -F; R³ es -alifático C₁₋₄ opcionalmente sustituido con 1 - 5 ocurrencias de R⁵; R⁴ es -alquil C₁₋₂ opcionalmente sustituido con 1 - 3 ocurrencias de R⁵; o R³ y R⁴ se toman juntos para formar un anillo saturado carbocíclico o heterocíclico de 3 - 7 miembros opcionalmente sustituido con 1 - 5 ocurrencias de R⁵; cada R⁵ se selecciona independientemente entre halógeno, -OCH₃, -OH, -NO₂, -NH₂, -SH, -SCH₃, -NHCH₃, -CN, o alifático C₁₋₂ insustituido, o dos grupos R⁵, junto con el carbono al que están ligados, forman un anillo ciclopropilo; R⁶ es -H o alquilo C₁₋₂ insustituido; y R⁷ es un -CH₂CR₃ o -(CH₂)₂CR₃ donde cada R es independientemente -H o -F; que comprende los pasos de: i) hacer reaccionar un compuesto de la fórmula (2) con una sal de clorhidrato de un compuesto de la fórmula (3) en presencia de agua, un solvente orgánico, una base y un catalizador de metal de transición para generar un compuesto de la fórmula (1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504351P | 2011-07-05 | 2011-07-05 | |
| US201261636296P | 2012-04-20 | 2012-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087069A1 true AR087069A1 (es) | 2014-02-12 |
Family
ID=46513874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102438A AR087069A1 (es) | 2011-07-05 | 2012-07-05 | Procesos e intermediarios para producir azaindoles |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8513414B2 (es) |
| EP (2) | EP3141548B9 (es) |
| JP (3) | JP2014520815A (es) |
| KR (1) | KR20140058547A (es) |
| CN (2) | CN103702998A (es) |
| AR (1) | AR087069A1 (es) |
| AU (1) | AU2012279046B2 (es) |
| BR (1) | BR112014000115A2 (es) |
| CA (1) | CA2839937C (es) |
| DK (1) | DK3141548T3 (es) |
| ES (1) | ES2804528T3 (es) |
| MX (1) | MX2013015147A (es) |
| NZ (2) | NZ714502A (es) |
| PL (1) | PL3141548T3 (es) |
| PT (1) | PT3141548T (es) |
| RU (1) | RU2014103806A (es) |
| TW (1) | TW201321378A (es) |
| WO (1) | WO2013006634A2 (es) |
| ZA (1) | ZA201400049B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1730146E (pt) * | 2004-03-30 | 2011-07-11 | Vertex Pharma | Azaindoles úteis como inibidores de jak e outras proteínas quinases |
| PH12015501678B1 (en) | 2009-06-17 | 2022-07-06 | Vertex Pharma | Inhibitors of influenza viruses replication |
| CN103702998A (zh) * | 2011-07-05 | 2014-04-02 | 沃泰克斯药物股份有限公司 | 生产氮杂吲哚类的方法和中间体 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2014201332A1 (en) | 2013-06-14 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical combinations useful for treating rheumatoid arthritis |
| MX2016002176A (es) | 2013-08-22 | 2016-06-23 | Vertex Pharma | Azaindoles enriquecidos isotopicamente. |
| US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
| AU2014348752C1 (en) * | 2013-11-13 | 2019-11-21 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| JP6615755B2 (ja) | 2013-11-13 | 2019-12-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インフルエンザウイルスの複製の阻害剤 |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| JP6704416B2 (ja) * | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| CN106854205B (zh) * | 2015-12-09 | 2019-07-09 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| CN105523986A (zh) * | 2015-12-30 | 2016-04-27 | 江汉大学 | 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法 |
| WO2018046428A1 (en) * | 2016-09-09 | 2018-03-15 | F. Hoffmann-La Roche Ag | Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole |
| US10577365B2 (en) | 2016-12-23 | 2020-03-03 | Felicitex Therapeutics, Inc. | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases |
| CN116473973A (zh) * | 2018-12-24 | 2023-07-25 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 |
| CN113121452A (zh) * | 2021-05-10 | 2021-07-16 | 甘肃堡昌化工有限公司 | 一种硫酸法尿嘧啶的精制工艺 |
| CN113851244A (zh) * | 2021-09-18 | 2021-12-28 | 浙江爱索拓科技有限公司 | 一种含放射性同位素碳-14废水的处理方法 |
| CN113896716A (zh) * | 2021-10-27 | 2022-01-07 | 浙江爱索拓科技有限公司 | 一种放射性同位素碳-14双标记甲磺酸伏美替尼合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| US20030004174A9 (en) | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
| UY26942A1 (es) * | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2003091246A1 (en) | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| TW200406385A (en) | 2002-05-31 | 2004-05-01 | Eisai Co Ltd | Pyrazole compound and pharmaceutical composition containing the same |
| WO2005033072A2 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Heterocyclic amides and sulfonamides |
| CN1914177B (zh) | 2004-01-30 | 2011-10-12 | 长濑产业株式会社 | 具有轴不对称性的光学活性季铵盐以及使用该季铵盐得到的α-氨基酸及其衍生物的制备方法 |
| PT1730146E (pt) * | 2004-03-30 | 2011-07-11 | Vertex Pharma | Azaindoles úteis como inibidores de jak e outras proteínas quinases |
| SI2332940T1 (sl) * | 2004-03-30 | 2013-03-29 | Vertex Pharmaceuticals Incorporated | Azaindoli, uporabni kot inhibitorji jak in drugih protein-kinaz |
| WO2006038001A1 (en) * | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| EP1881983B1 (en) | 2005-05-20 | 2012-01-11 | Vertex Pharmaceuticals, Inc. | Pyrrolopyridines useful as inhibitors of protein kinase |
| CN101374839A (zh) * | 2006-01-17 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| NZ601687A (en) | 2006-01-17 | 2014-03-28 | Vertex Pharma | Azaindoles useful as inhibitors of janus kinases |
| EP2038272B8 (en) * | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| DK2050749T3 (en) * | 2006-08-08 | 2018-01-08 | Chugai Pharmaceutical Co Ltd | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF |
| ATE497961T1 (de) | 2006-12-14 | 2011-02-15 | Vertex Pharma | Als proteinkinaseinhibitoren geeignete verbindungen |
| JP5555635B2 (ja) * | 2007-11-05 | 2014-07-23 | ノバルティス アーゲー | 高脂血症または動脈硬化症などの疾患の処置に有用なｃｅｔｐ阻害剤としての４−ベンジルアミノ−１−カルボキシアシル−ピペリジン誘導体 |
| PL2247592T3 (pl) * | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
| PH12015501678B1 (en) | 2009-06-17 | 2022-07-06 | Vertex Pharma | Inhibitors of influenza viruses replication |
| CN103702998A (zh) | 2011-07-05 | 2014-04-02 | 沃泰克斯药物股份有限公司 | 生产氮杂吲哚类的方法和中间体 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| EP2776036A1 (en) | 2011-11-07 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
| MX2016002176A (es) | 2013-08-22 | 2016-06-23 | Vertex Pharma | Azaindoles enriquecidos isotopicamente. |
-
2012
- 2012-07-03 CN CN201280036682.0A patent/CN103702998A/zh active Pending
- 2012-07-03 MX MX2013015147A patent/MX2013015147A/es not_active Application Discontinuation
- 2012-07-03 CN CN201610811795.3A patent/CN106432311A/zh active Pending
- 2012-07-03 US US13/541,504 patent/US8513414B2/en not_active Expired - Fee Related
- 2012-07-03 BR BR112014000115A patent/BR112014000115A2/pt not_active IP Right Cessation
- 2012-07-03 KR KR1020147003091A patent/KR20140058547A/ko not_active Withdrawn
- 2012-07-03 AU AU2012279046A patent/AU2012279046B2/en not_active Ceased
- 2012-07-03 NZ NZ714502A patent/NZ714502A/en not_active IP Right Cessation
- 2012-07-03 RU RU2014103806/04A patent/RU2014103806A/ru not_active Application Discontinuation
- 2012-07-03 EP EP16190960.1A patent/EP3141548B9/en active Active
- 2012-07-03 PL PL16190960T patent/PL3141548T3/pl unknown
- 2012-07-03 EP EP12735411.6A patent/EP2729465A2/en not_active Withdrawn
- 2012-07-03 JP JP2014519264A patent/JP2014520815A/ja not_active Withdrawn
- 2012-07-03 NZ NZ619699A patent/NZ619699A/en not_active IP Right Cessation
- 2012-07-03 ES ES16190960T patent/ES2804528T3/es active Active
- 2012-07-03 CA CA2839937A patent/CA2839937C/en active Active
- 2012-07-03 DK DK16190960.1T patent/DK3141548T3/da active
- 2012-07-03 PT PT161909601T patent/PT3141548T/pt unknown
- 2012-07-03 WO PCT/US2012/045431 patent/WO2013006634A2/en not_active Ceased
- 2012-07-04 TW TW101124076A patent/TW201321378A/zh unknown
- 2012-07-05 AR ARP120102438A patent/AR087069A1/es unknown
-
2013
- 2013-07-12 US US13/940,421 patent/US8796453B2/en not_active Expired - Fee Related
-
2014
- 2014-01-06 ZA ZA2014/00049A patent/ZA201400049B/en unknown
- 2014-06-25 US US14/314,158 patent/US8946425B2/en active Active
- 2014-12-15 US US14/570,044 patent/US9090614B2/en not_active Expired - Fee Related
-
2015
- 2015-06-17 US US14/741,499 patent/US20150284388A1/en not_active Abandoned
-
2016
- 2016-07-22 JP JP2016144361A patent/JP2017002067A/ja not_active Withdrawn
-
2018
- 2018-07-19 JP JP2018135847A patent/JP6761448B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087069A1 (es) | Procesos e intermediarios para producir azaindoles | |
| AR124483A2 (es) | Compuestos heterocíclicos útiles como inhibidores de pdk1 | |
| AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
| AR124117A2 (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ES2585330T3 (es) | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto inhibitorio en la producción de quinurenina | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR105820A1 (es) | Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5 | |
| ES2677919T3 (es) | Aminoalquil-quinazolonas sustituidas con pirimidina como inhibidores de la fosfatidilinositol 3-quinasa | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| AR099995A1 (es) | Piridilamidinas fungicidas | |
| AR091424A1 (es) | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR092869A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| AR088327A1 (es) | Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunes | |
| AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR090203A1 (es) | Compuestos heterobiciclicos como inhibidores de pde10 | |
| UY32863A (es) | COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR087771A1 (es) | Moduladores de la pde10 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |